-
Something wrong with this record ?
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
R. Aiglova, M. Taborsky, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, V. Cernicek, M. Vicha, T. Skala
Language English Country Czech Republic
Document type Journal Article, Observational Study
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
34092792
DOI
10.5507/bp.2021.035
Knihovny.cz E-resources
- MeSH
- Angiotensins therapeutic use MeSH
- Angiotensin Receptor Antagonists * therapeutic use MeSH
- Antihypertensive Agents MeSH
- Angiotensin II Type 2 Receptor Blockers therapeutic use MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Humans MeSH
- Losartan therapeutic use MeSH
- Neprilysin therapeutic use MeSH
- Perindopril therapeutic use MeSH
- Ramipril therapeutic use MeSH
- Retrospective Studies MeSH
- Heart Failure * drug therapy epidemiology MeSH
- Telmisartan therapeutic use MeSH
- Valsartan therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Geographicals
- Czech Republic MeSH
AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II-receptor antagonists (ARB) and angiotensin receptor blocker/neprilysin inhibitor (ARNI) use. METHODS AND RESULTS: ACEi and ARBs were generally used in 87.6% of all HF patients in 2012 (n=154 627); 84.5% in 2013 (n=170 861); 83.5% in 2014 (n=186 963); 81.6% in 2015 (n=198 844); 80.1% in 2016 (n=205 793); 78.0% in 2017 (n=212 152) and in 76.7% in 2018 (n=219 235). In a sub-analysis of patients with a medical procedure and/or examination using an I50.x ICD code accounted for in the given year, ACEi and ARBs were generally used in 99.3% in 2012 (n=63 250); 96% in 2013 (n=62 241); 95.2% in 2014 (n=64 414); 93.3% in 2015 (n=65 217); 91.8% in 2016 (n=65 236); 90.1% in 2017 (n=65 761) and in 88.6% in 2018 (n=66 332). In 2018, the majority of patients with HF were prescribed ramipril (n=49 909; 17.5%) and perindopril (n=44 332; 15.5%). The mostly prescribed ARBs in 2018 were telmisartan (n=18 669; 6.5%); losartan (n=13 935; 4.9%) and valsartan (n=4 849; 1.7%). In 24.5% of cases, ACEIs and ARBs were prescribed in a fixed combination with another drug. ARNI became gradually more prescribed from 2018 (n=9 659 in November 2020). CONCLUSION: In an analysis of ACEIs, ARBs and ARNIs utilization in all patients treated for heart failure in the given year in the whole country, we found a comparable rate of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Ramipril and perindopril remained the mostly prescribed ACEIs and telmisartan became the mostly prescribed ARB. Since 2018, ARNIs began to be widely prescribed.
Bata's Regional Hospital Zlin Czech Republic
Cardio center Regional Hospital Karlovy Vary Karlovy Vary Czech Republic
Department of Internal Medicine 1 Cardiology University Hospital Olomouc Olomouc Czech Republic
Department of Internal Medicine Military University Hospital Prague Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22022915
- 003
- CZ-PrNML
- 005
- 20230118155259.0
- 007
- ta
- 008
- 221007s2022 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2021.035 $2 doi
- 035 __
- $a (PubMed)34092792
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Aiglová, Renáta $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0227652
- 245 10
- $a Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic / $c R. Aiglova, M. Taborsky, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, V. Cernicek, M. Vicha, T. Skala
- 520 9_
- $a AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II-receptor antagonists (ARB) and angiotensin receptor blocker/neprilysin inhibitor (ARNI) use. METHODS AND RESULTS: ACEi and ARBs were generally used in 87.6% of all HF patients in 2012 (n=154 627); 84.5% in 2013 (n=170 861); 83.5% in 2014 (n=186 963); 81.6% in 2015 (n=198 844); 80.1% in 2016 (n=205 793); 78.0% in 2017 (n=212 152) and in 76.7% in 2018 (n=219 235). In a sub-analysis of patients with a medical procedure and/or examination using an I50.x ICD code accounted for in the given year, ACEi and ARBs were generally used in 99.3% in 2012 (n=63 250); 96% in 2013 (n=62 241); 95.2% in 2014 (n=64 414); 93.3% in 2015 (n=65 217); 91.8% in 2016 (n=65 236); 90.1% in 2017 (n=65 761) and in 88.6% in 2018 (n=66 332). In 2018, the majority of patients with HF were prescribed ramipril (n=49 909; 17.5%) and perindopril (n=44 332; 15.5%). The mostly prescribed ARBs in 2018 were telmisartan (n=18 669; 6.5%); losartan (n=13 935; 4.9%) and valsartan (n=4 849; 1.7%). In 24.5% of cases, ACEIs and ARBs were prescribed in a fixed combination with another drug. ARNI became gradually more prescribed from 2018 (n=9 659 in November 2020). CONCLUSION: In an analysis of ACEIs, ARBs and ARNIs utilization in all patients treated for heart failure in the given year in the whole country, we found a comparable rate of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Ramipril and perindopril remained the mostly prescribed ACEIs and telmisartan became the mostly prescribed ARB. Since 2018, ARNIs began to be widely prescribed.
- 650 _2
- $a blokátory receptoru typu 2 pro angiotensin II $x terapeutické užití $7 D057912
- 650 12
- $a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
- 650 _2
- $a inhibitory ACE $x terapeutické užití $7 D000806
- 650 _2
- $a angiotensiny $x terapeutické užití $7 D000809
- 650 _2
- $a antihypertenziva $7 D000959
- 650 12
- $a srdeční selhání $x farmakoterapie $x epidemiologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a losartan $x terapeutické užití $7 D019808
- 650 _2
- $a neprilysin $x terapeutické užití $7 D015260
- 650 _2
- $a perindopril $x terapeutické užití $7 D020913
- 650 _2
- $a ramipril $x terapeutické užití $7 D017257
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a telmisartan $x terapeutické užití $7 D000077333
- 650 _2
- $a valsartan $x terapeutické užití $7 D000068756
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Táborský, Miloš, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $d 1962- $7 jn20010310074
- 700 1_
- $a Lazárová, Marie $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0074090
- 700 1_
- $a Pavlů, Luděk $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0236019
- 700 1_
- $a Daněk, Josef $u Department of Internal Medicine, Military University Hospital Prague, Prague, Czech Republic $7 xx0242063
- 700 1_
- $a Přeček, Jan, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $d 1985- $7 xx0154445
- 700 1_
- $a Schee, Alexandr $u Cardio center, Regional Hospital Karlovy Vary, Karlovy Vary, Czech Republic $7 xx0134780
- 700 1_
- $a Gloger, Vít $u Bata's Regional Hospital, Zlin, Czech Republic $7 xx0209738
- 700 1_
- $a Černíček, Vlastimil $u Bata's Regional Hospital, Zlin, Czech Republic $7 xx0244011
- 700 1_
- $a Vícha, Marek $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0229304
- 700 1_
- $a Skála, Tomáš $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0137536
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 166, č. 3 (2022), s. 322-327
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34092792 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20221007 $b ABA008
- 991 __
- $a 20230118155253 $b ABA008
- 999 __
- $a ok $b bmc $g 1885621 $s 1174201
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 166 $c 3 $d 322-327 $e 20210604 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK138 $a Pubmed-20221007
